Valuation of viral vector manufacturing spinout

Challenge: A listed biotechnology company had developed a significant capability in viral vector manufacturing and was considering spinning it out into a joint venture with a major CDMO. The client...
Learn More

Valuation of Phase 3 Ready Alzheimer's Drug

Challenge: A clinical stage company developed two series of small molecules to treat Alzheimer Disease (AD) and other central nervous system (CNS) indications. Their lead asset aims for symptomatic...
Learn More

Virtual Stewardship of a Targeted Cancer Therapy to an IND Submission

An early-stage biotech company developing a targeted cancer therapy engaged Alacrita to provide expertise to help them navigate an upcoming IND submission. An Alacrita partner and medical oncologist...
Learn More

Valuation of a cancer therapy for licensing deal

Challenge: A biotech company developing small molecule drugs for oncology was in the process of licensing negotiations with a pharma company for its lead asset. The asset, set to enter the clinic in...
Learn More

Oncology asset valuation for fundraising support

Challenge: A clinical stage biotech company developing novel oncology treatments was planning a private funding round to progress the clinical development of its lead product. The biotech requested...
Learn More

Valuation of pipeline for fundraising activities

Challenge: An oncology biotech company with a proprietary therapeutics development platform technology was in the process of fundraising activities. The company's pipeline included three main...
Learn More

Valuation and deal making for oncology antibody

Challenge: A biotechnology company developing novel multi-specific antibody therapeutics to treat a range of cancers asked Alacrita to develop valuations for its four leading assets, as well as...
Learn More

Valuation of drug discovery company with Monte Carlo simulation

Challenge: A drug discovery company preparing for a forthcoming funding round wanted to update a valuation of the business based on a series of contract research projects and the proprietary value in...
Learn More

Dermatology due diligence and valuation

Challenge Alacrita’s pharma consultants were engaged to conduct a due diligence and valuation of a Phase II dermatology asset.
Learn More

Valuation of a first in class, clinical stage small molecule to treat a range of tumor types

Challenge A private biotech company was preparing for an IPO. The company was developing a first-in-class small molecule inhibitor with the potential to treat a range of tumor types. The company was...
Learn More

Valuation and Partnering Support

Challenge A biotech company engaged in licensing discussions with a number of major pharma companies needed help with risk adjusted NPV (rNPV) valuations for each program.
Learn More

Monetizing oncology royalty streams

Challenge A licensor of a marketed oncology drug needed support with monetizing its royalty stream. Alacrita was engaged to develop an independent market-based valuation of the product.
Learn More
1 2